Endo to Participate at the UBS Global Healthcare Conference
DUBLIN, May 2, 2018 /PRNewswire/ --Endo International plc (NASDAQ: ENDP) announced today that Paul Campanelli, President and CEO, will participate in a fireside chat at the UBS Global Healthcare Conference in New York City on Monday, May 21, 2018 at 11:00 a.m. ET.
A live webcast and audio archive for the event will be available on the Company's website at http://investor.endo.com/events-and-presentations. Participants should allow approximately 10 minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast.
About Endo International plc Endo International plc (NASDAQ: ENDP) is a highly focused generics and specialty branded pharmaceutical company delivering quality medicines to patients in need through excellence in development, manufacturing and commercialization. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, PA. Learn more at www.endo.com.
In the news release, OSR Holdings and SillaJen have entered into a Memorandum of Understanding to collaboratively pursue the development of innovative therapeutics and enter the U.S. market, issued 22-Apr-2024 by OSR Holdings over PR Newswire, we are...
Beyond2020, the flagship initiative launched by the Zayed Sustainability Prize, the UAE's pioneering award for sustainability and humanitarianism, today announced the deployment of AI-powered mammography services across Costa Rica to support the...
Surrey FA and Chelsea FC Foundation are proud to announce their collaborative effort once again to offer empowering coaching sessions to female refugees in the local community. These sessions will provide an opportunity for women to engage with...
BeiGene, Ltd. , a global oncology company, today announced that the European Commission (EC) has approved tislelizumab as a treatment for non-small cell lung cancer (NSCLC) across three indications, including first- and second-line use....
Vizient, Inc. hosted its inaugural Insight: Cell, Gene, and Specialty Pharmacy Symposium, bringing together leading healthcare providers, payers and manufacturers of high-cost, ultra-specialty pharmaceuticals along with other stakeholders to discuss...
